What validated risk prediction tool can be used to assess a patient's risk for Clostridioides difficile infection, including its scoring criteria and management recommendations for high‑risk patients?

Risk Prediction for Clostridioides difficile Infection

While no single validated risk prediction tool is universally endorsed by major guidelines for routine clinical use, several validated models exist that can identify high-risk patients at hospital admission, with the most practical approach being clinical assessment using established risk factors rather than formal scoring systems.

Available Risk Prediction Models

The evidence base includes several validated prediction models, though none are specifically recommended in the IDSA/SHEA guidelines 1:

Most Validated Models

Hospital-Onset CDI Risk Score 2

• Developed from 78,080 admissions with excellent discrimination (c-statistic 0.88)
• 14 independent predictors identified at admission:
  • Hospital community-onset CDI pressure
  • Age ≥65 years
  • Previous healthcare exposures within 60 days
  • CDI in previous admission
  • ICU admission
  • Albumin ≤3 g/dL
  • Creatinine >2.0 mg/dL
  • Bands >32%
  • Platelets ≤150 or >420 × 10⁹/L
  • White blood cell count >11,000/mm³
  • Days of high-risk antibiotic treatment
  • Receipt of laxatives, gastric acid suppressors, or antimotility drugs
  • Modified Acute Physiology Score

Simplified Two-Factor Model 3

• Most practical for immediate implementation
• Key predictors:
  • Age ≥70 years (adjusted OR 1.89)
  • Recent hospitalization in past 90 days (adjusted OR 3.55)
• Score ≥2 had 76% sensitivity, 49% specificity, 63% accuracy
• Fair discrimination (AUC 0.7) but easily obtainable at admission

European Validated Model 4

• Excellent discrimination (AUC 0.84 derivation, 0.81 external validation)
• Independent predictors:
  • Age >65 years
  • Recent hospitalization
  • CDI history
  • Malignancy
  • Chronic renal failure
  • Immunosuppressant use
  • Antibiotics before admission
  • Nonsurgical admission
  • ICU admission
  • Gastric tube feeding
  • Cephalosporin treatment
  • Underlying infection present

Clinical Risk Factors from Guidelines

The IDSA/SHEA and WSES guidelines emphasize clinical risk factor assessment rather than formal scoring 1, 5, 6, 5:

Primary Risk Factors

• Antibiotic exposure (most important risk factor)
• Age >65 years (RR 1.63)
• Prolonged hospitalization
• Proton pump inhibitor use (RR 1.58)
• Inflammatory bowel disease
• Oncological diseases
• Hematopoietic stem cell transplantation
• Chronic kidney disease/end-stage renal disease (RR 1.59)
• Mechanical ventilation
• Fluoroquinolone exposure (RR 1.42)

Recurrence Risk Factors 6, 5

• Previous CDI episodes (OR 3.87)
• Concurrent antibiotic use (RR 1.76)
• Advanced age >65 years
• Immunocompromising conditions
• Severe initial disease
• Hypervirulent strains

Management Recommendations for High-Risk Patients

Prevention Strategies

Antibiotic stewardship is paramount 1:

• Discontinue unnecessary antibiotics as soon as possible (strong recommendation, moderate quality evidence)
• Early identification allows targeted antimicrobial modifications 7
• Models can identify 55% of future CDI cases at admission, with 1 in 32 high-risk patients testing positive

Severity Assessment at Diagnosis

The guidelines provide clear severity criteria rather than prediction scores 1, 6:

Non-severe CDI:

• WBC ≤15,000 cells/mL AND
• Serum creatinine <1.5 mg/dL

Severe CDI:

• WBC ≥15,000 cells/mL OR
• Serum creatinine >1.5 mg/dL

Fulminant CDI:

• Hypotension or shock
• Ileus
• Megacolon

Treatment Based on Risk Stratification

Initial Episode, Non-severe 1:

• Vancomycin 125 mg PO 4 times daily × 10 days OR
• Fidaxomicin 200 mg PO twice daily × 10 days
• (Strong recommendation, high quality evidence)

Initial Episode, Severe 1, 5, 1:

• Vancomycin 125 mg PO 4 times daily × 10 days OR
• Fidaxomicin 200 mg PO twice daily × 10 days
• (Strong recommendation, high quality evidence)

Fulminant CDI 1, 6:

• Vancomycin 500 mg PO 4 times daily
• PLUS IV metronidazole 500 mg every 8 hours
• Consider rectal vancomycin if ileus present (500 mg in 100 mL NS every 6 hours)
• Prompt surgical evaluation (strong recommendation)

Recurrence Prevention in High-Risk Patients

For patients at high recurrence risk 8:

• Consider bezlotoxumab as co-intervention (reduces recurrence by 38%, moderate quality evidence)
• Particularly beneficial in elderly or those requiring concurrent antibiotics 5

First Recurrence 1:

• Tapered/pulsed vancomycin regimen OR
• Fidaxomicin 200 mg twice daily × 10 days

Multiple Recurrences 1, 6:

• Fecal microbiota transplantation after ≥2 recurrences (strong recommendation, moderate quality evidence)
• 70-92% success rates with FMT 6

Practical Implementation

The most clinically useful approach combines:

1. At admission: Screen for age ≥70 years + recent hospitalization (past 90 days) as immediate red flags 3

2. During hospitalization: Monitor for additional risk factors (antibiotics, PPI use, renal dysfunction, albumin <2.5 g/dL) 5, 6

3. At CDI diagnosis: Use guideline severity criteria (WBC, creatinine) rather than prediction scores to guide treatment intensity 1

4. For recurrence risk: Assess previous CDI episodes, ongoing antibiotic needs, and immunocompromised status to determine need for bezlotoxumab or extended therapy 8

Important Caveats

• Guidelines acknowledge that severity criteria are based on expert opinion and may need prospective validation 1
• Risk factors have limitations in patients with baseline leukopenia (hematologic malignancy) or end-stage renal disease 6
• Clinical judgment remains essential alongside any scoring system 6
• The simplified two-factor model 3 offers the most practical bedside application but has only fair discrimination
• More complex models 4, 2, 9 have better discrimination but require electronic health record integration for practical use